NCT04616183 - LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal AdenocarcinomaRecurrent Colorectal CarcinomaStage III Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Colon Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Rectal Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IIIC Rectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVA Rectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVB Rectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage IVC Rectal Cancer AJCC v8Unresectable Colon AdenocarcinomaUnresectable Colorectal CarcinomaUnresectable Rectal Adenocarcinoma

Interventions

DRUG

Abemaciclib

Given PO

BIOLOGICAL

Cetuximab

Given IV

DRUG

ERK1/2 Inhibitor LY3214996

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER